Video Experimental Relacionado

Updated: Jul 5, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Tau en plasma: validación analítica y clínica del primer inmunoensayo comercial

Michel N Nafash^1,2,3, Sarah E Svirsky⁴, Xuemei Zeng^1,2,3

¹Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Scientific reports

|February 21, 2026

Resumen

No abstract available in PubMed .

Palabras clave:

Enfermedad de Alzheimer Validación analítica Biomarcadores en sangre Tau de origen cerebral Validación clínica Lesión cerebral traumática

Más Videos Relacionados

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening

Published on: November 20, 2018

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

Videos de Conceptos Relacionados

Enzyme-Linked Immunosorbent Assay

Enzyme-Linked Immunosorbent Assay

In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen. Enzyme-substrate reaction allows the antigen to be visualized or quantified.